Rituxan looks to become new front-line option in chronic lymphocytic leukaemia
This article was originally published in Scrip
Genentech/Roche/Biogen Idec's Rituxan/MabThera (rituximab) has delayed disease progression in chronic lymphocytic leukaemia (CLL) by about 10 months in two Phase III trials whose data were recently presented at the American Society of Hematology (ASH) meeting in San Francisco.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.